IP Library › Granted Patent US 7,803,552
Granted Patent B2
US 7,803,552 · App. 12/607,036 · Granted Sep 28, 2010

Biomarkers for predicting prostate cancer progression

Assignee: The Brigham & Women's Hospital, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,552
App. No.
12/607,036
Granted
Sep 28, 2010
Kind
B2
Abstract

The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression.

Claims (36)

1. A kit for diagnosing prostate disease in a subject, said kit comprising:

a set of reagents that specifically detects expression levels of a set of genes comprising ABP280 (FLNA) and at least three or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52; and

instructions for using said kit for diagnosing prostate disease in the subject.

2. The kit of claim 1 , wherein the set of reagents detects the expression of mRNA expressed from said set of genes.

3. The kit of claim 2 , wherein the set of reagents comprises nucleic acid probes complementary to mRNA expressed from said set of genes.

4. The kit of claim 3 , wherein the nucleic acid probes complementary to mRNA are cDNA or oligonucleotides.

5. The kit of claim 3 , wherein the nucleic acid probes complementary to mRNA are immobilized on a substrate surface.

6. The kit of claim 1 , wherein the set of reagents detects the expression of polypeptides encoded by said set of genes.

7. The kit of claim 6 , wherein the set of reagents comprises antibodies that specifically bind to the polypeptides encoded by said set of genes.

8. The kit of claim 1 , wherein the kit further comprises one prostate disease expression profile map.

9. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA) and at least four or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

10. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA) and at least five or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

11. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA) and at least six or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

12. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA) and at least seven or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

13. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA) and at least eight or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

14. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA) and at least nine or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

15. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA) and at least ten or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

16. The kit of claim 1 , wherein the set of genes comprises ABP280 (FLNA), AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

17. A kit for providing a prognosis for prostate disease in a subject, said kit comprising:

a set of reagents that specifically detects expression levels of a set of genes comprising ABP280 (FLNA) and at least three or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52; and

instructions for using said kit for providing a prognosis for prostate disease in the subject.

18. The kit of claim 17 , wherein the set of reagents detects the expression of mRNA expressed from said set of genes.

19. The kit of claim 18 , wherein the set of reagents comprises nucleic acid probes complementary to mRNA expressed from said set of genes.

20. The kit of claim 19 , wherein the nucleic acid probes complementary to mRNA are cDNA or oligonucleotides.

21. The kit of claim 19 , wherein the nucleic acid probes complementary to mRNA are immobilized on a substrate surface.

22. The kit of claim 17 , wherein the set of reagents detects the expression of polypeptides encoded by said genes.

23. The kit of claim 22 , wherein the set of reagents comprises antibodies that specifically bind to polypeptides encoded by said set of genes.

24. The kit of claim 17 , further comprising at least one prostate disease expression profile map.

25. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA) and at least four or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

26. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA) and at least five or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

27. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA) and at least six or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

28. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA) and at least seven or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

29. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA) and at least eight or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

30. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA) and at least nine or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

31. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA) and at least ten or more of genes selected from the group consisting of AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

32. The kit of claim 17 , wherein the set of genes comprises ABP280 (FLNA), AMACR, CDK7, ITGA5, JAGGED1, KANADAPTIN, MIB1 (MKI67), MTA1, MUC1, p63, PSA(KLK3), and TPD52.

Assignments (1)
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER: 11361517 FILING DATE: 02/24/2006 PREVIOUSLY RECORDED ON REEL 023494 FRAME 0441. ASSIGNOR(S) HEREBY CONFIRMS THE SERIAL NUMBER: 12607036 FILING DATE: 10/27/2009. Recorded Dec 11, 2009
From: RUBIN, MARK A.; DEMICHELIS, FRANCESCA
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 023640/0688 →
Continuity (3)
Division 1136151700 · Feb 24, 2006
Provisional Application 6065648900 · Feb 25, 2005
Related Publication 20100137164A1 · Jun 3, 2010